CompletedNCT01004965
Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720
Studying Acute myeloid leukemia with 11q23 abnormalities
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Maria R. Baer, MDUniversity of Maryland Greenebaum Cancer Center
- Intervention
- laboratory biomarker analysis(other)
- Enrollment
- 2034 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1997 – 2010
Study locations (30)
- Naval Medical Center - San Diego, San Diego, California, United States
- Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States
- CCOP - Christiana Care Health Services, Newark, Delaware, United States
- Walter Reed Army Medical Center, Washington D.C., District of Columbia, United States
- University of Illinois Cancer Center, Chicago, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
- Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
- Menorah Medical Center, Overland Park, Kansas, United States
- Saint Luke's Hospital - South, Overland Park, Kansas, United States
- Shawnee Mission Medical Center, Shawnee Mission, Kansas, United States
- CancerCare of Maine at Eastern Maine Medical Center, Bangor, Maine, United States
- Union Hospital Cancer Program at Union Hospital, Elkton, Maryland, United States
- Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
- Truman Medical Center - Hospital Hill, Kansas City, Missouri, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01004965 on ClinicalTrials.govOther trials for Acute myeloid leukemia with 11q23 abnormalities
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06710418Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/LeukemiaUniversity of Washington
- RECRUITINGPHASE3NCT07007312Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLKura Oncology, Inc.
- RECRUITINGPHASE1, PHASE2NCT06928662Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of RelapseFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT07106749CD180 CART for Relapsed or Refractory CD180 Positive Hematologic MalignanciesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT06448013A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06245746UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid LeukemiaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNCT06452732Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AMLPeking University People's Hospital
- RECRUITINGNCT06458257The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid LeukemiaRuijin Hospital
See all trials for Acute myeloid leukemia with 11q23 abnormalities →